Interim analysis of a phase I/IIa trial assessing E39+GM-CSF, a folate binding protein vaccine, to prevent recurrence in ovarian and endometrial cancer patients

Doreen O. Jackson; Kevin Byrd; Timothy J. Vreeland; Diane F. Hale; Garth S. Herbert; Julia M. Greene; Erika J. Schneble; John S. Berry; Alfred F. Trappey; Guy Travis Clifton; Mark O. Hardin; Jonathan Martin; John C. Elkas; Thomas P. Conrads; Kathleen M. Darcy; Chad A. Hamilton; George L. Maxwell; George E. Peoples

doi:10.18632/oncotarget.13305

Interim analysis of a phase I/IIa trial assessing E39+GM-CSF, a folate binding protein vaccine, to prevent recurrence in ovarian and endometrial cancer patients

Oncotarget ◽

10.18632/oncotarget.13305 ◽

2016 ◽

Vol 8 (9) ◽

pp. 15912-15923 ◽

Cited By ~ 6

Author(s):

Doreen O. Jackson ◽

Kevin Byrd ◽

Timothy J. Vreeland ◽

Diane F. Hale ◽

Garth S. Herbert ◽

...

Keyword(s):

Endometrial Cancer ◽

Phase I ◽

Cancer Patients ◽

Interim Analysis ◽

Binding Protein ◽

Protein Vaccine ◽

Folate Binding Protein ◽

Gm Csf

Download Full-text

Interim analysis of a phase I/IIA trial assessing E39+GM-CSF, a folate binding protein vaccine, to prevent recurrence in ovarian and endometrial cancer patients

Gynecologic Oncology ◽

10.1016/j.ygyno.2017.03.068 ◽

2017 ◽

Vol 145 ◽

pp. 23

Author(s):

G.L. Maxwell ◽

J.C. Elkas ◽

T.P. Conrads ◽

K.M. Darcy ◽

C.A. Hamilton ◽

...

Keyword(s):

Endometrial Cancer ◽

Phase I ◽

Cancer Patients ◽

Interim Analysis ◽

Binding Protein ◽

Protein Vaccine ◽

Folate Binding Protein ◽

Gm Csf

Download Full-text

The primary analysis of a phase I/IIa dose finding trial of a folate binding protein vaccine, E39 + GM-CSF in ovarian and endometrial cancer patients to prevent recurrence.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.5576 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. 5576-5576

Author(s):

Doreen O Jackson ◽

Timothy J. Vreeland ◽

Julia M. Greene ◽

Diane F. Hale ◽

Erika J Schneble ◽

...

Keyword(s):

Endometrial Cancer ◽

Phase I ◽

Cancer Patients ◽

Binding Protein ◽

Dose Finding ◽

Protein Vaccine ◽

Primary Analysis ◽

Folate Binding Protein ◽

Gm Csf

Download Full-text

2764 Preliminary results of the phase I/IIa dose finding trial of a folate binding protein vaccine (E39+GM-CSF) in ovarian and endometrial cancer patients to prevent recurrence

European Journal of Cancer ◽

10.1016/s0959-8049(16)31530-1 ◽

2015 ◽

Vol 51 ◽

pp. S552

Author(s):

J.M. Greene ◽

E.J. Schneble ◽

J.S. Berry ◽

A.F. Trappey ◽

G.T. Clifton ◽

...

Keyword(s):

Endometrial Cancer ◽

Phase I ◽

Cancer Patients ◽

Binding Protein ◽

Dose Finding ◽

Protein Vaccine ◽

Folate Binding Protein ◽

Preliminary Results ◽

Gm Csf

Download Full-text

Preliminary results of the phase I/IIa dose finding trial of a folate binding protein vaccine (E39+GM-CSF) in ovarian and endometrial cancer patients to prevent recurrence.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.e14031 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. e14031-e14031 ◽

Cited By ~ 1

Author(s):

Julia M. Greene ◽

Erika J Schneble ◽

John S. Berry ◽

Alfred F. Trappey ◽

Timothy J. Vreeland ◽

...

Keyword(s):

Endometrial Cancer ◽

Phase I ◽

Cancer Patients ◽

Binding Protein ◽

Dose Finding ◽

Protein Vaccine ◽

Folate Binding Protein ◽

Preliminary Results ◽

Gm Csf

Download Full-text

Final analysis of a phase I/IIa trial of the folate‐binding protein‐derived E39 peptide vaccine to prevent recurrence in ovarian and endometrial cancer patients

Cancer Medicine ◽

10.1002/cam4.2378 ◽

2019 ◽

Vol 8 (10) ◽

pp. 4678-4687 ◽

Cited By ~ 1

Author(s):

Tommy A. Brown ◽

Kevin Byrd ◽

Timothy J. Vreeland ◽

Guy T. Clifton ◽

Doreen O. Jackson ◽

...

Keyword(s):

Endometrial Cancer ◽

Phase I ◽

Cancer Patients ◽

Binding Protein ◽

Peptide Vaccine ◽

Final Analysis ◽

Folate Binding Protein

Download Full-text

Preliminary results of the Phase IIa trial of a folate binding protein (FBP) adjuvant cancer vaccine (E39+GM-CSF) in ovarian and endometrial cancer patients to prevent recurrence

Journal for ImmunoTherapy of Cancer ◽

10.1186/2051-1426-2-s3-p74 ◽

2014 ◽

Vol 2 (S3) ◽

Author(s):

Julia Greene ◽

Erika Schneble ◽

John Berry ◽

Alfred Trappey ◽

Timothy Vreeland ◽

...

Keyword(s):

Endometrial Cancer ◽

Cancer Patients ◽

Cancer Vaccine ◽

Binding Protein ◽

Folate Binding Protein ◽

Preliminary Results ◽

Gm Csf

Download Full-text

Abstract P6-10-04: Determining the optimal vaccination strategy using a combination of the folate binding protein (FBP) peptide vaccine (E39+GM-CSF) and an attenuated version (E39') to maximize the immunologic response in breast cancer patients

10.1158/1538-7445.sabcs16-p6-10-04 ◽

2017 ◽

Author(s):

DO Jackson ◽

N Qiao ◽

KM Peace ◽

DF Hale ◽

TJ Vreeland ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Binding Protein ◽

Peptide Vaccine ◽

Vaccination Strategy ◽

Immunologic Response ◽

Breast Cancer Patients ◽

Folate Binding Protein ◽

Gm Csf

Download Full-text

Abstract B007: Improved disease-free survival in endometrial and ovarian cancer patients with low folate binding protein expression after treatment with the E39 peptide vaccine in a Phase I/IIa trial

10.1158/2326-6066.imm2016-b007 ◽

2016 ◽

Author(s):

Kaitlin M. Peace ◽

Diane F. Hale ◽

Timothy J. Vreeland ◽

Doreen O. Jackson ◽

Julia M. Greene ◽

...

Keyword(s):

Ovarian Cancer ◽

Protein Expression ◽

Phase I ◽

Cancer Patients ◽

Binding Protein ◽

Peptide Vaccine ◽

Disease Free Survival ◽

Folate Binding Protein ◽

Free Survival ◽

Disease Free

Download Full-text

Abstract CT073: Comparing an attenuated booster (E39’) vs E39 booster to potentiate the clinical benefit of the folate binding protein (FBP)-derived vaccine (E39 + GM-CSF) in a phase I/IIa trial to prevent recurrence in endometrial (EC) and ovarian cancer (OC) patients

10.1158/1538-7445.am2016-ct073 ◽

2016 ◽

Author(s):

Doreen O. Jackson ◽

Timothy J. Vreeland ◽

Diane F. Hale ◽

Garth S. Herbert ◽

Julia M. Greene ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase I ◽

Clinical Benefit ◽

Binding Protein ◽

Folate Binding Protein ◽

Gm Csf

Download Full-text

Phase I/II Trial of Melanoma Patient–Specific Vaccine of Proliferating Autologous Tumor Cells, Dendritic Cells, and GM-CSF: Planned Interim Analysis

Cancer Biotherapy & Radiopharmaceuticals ◽

10.1089/1084978042484759 ◽

2004 ◽

Vol 19 (5) ◽

pp. 658-665 ◽

Cited By ~ 2

Author(s):

Robert Dillman ◽

Senthamil Selvan ◽

Patric Schiltz ◽

Cheryl Peterson ◽

Kanoe Allen ◽

...

Keyword(s):

Dendritic Cells ◽

Phase I ◽

Tumor Cells ◽

Melanoma Patient ◽

Interim Analysis ◽

Patient Specific ◽

Autologous Tumor ◽

Gm Csf

Download Full-text